Keyphrases
Spain
100%
Biological Agents
100%
Asthma Patients
100%
Severe Eosinophilic Asthma
100%
Anti-IL-5
100%
Benralizumab
100%
Oral Corticosteroids
66%
Corticosteroid Treatment
66%
Exacerbation Rate
50%
Severe Exacerbations
50%
Early Access
33%
Asthma
33%
Specialist Visits
33%
Treatment Dose
33%
Emergency Department Visits
33%
Dose Reduction
33%
Primary Care Visits
33%
Asthma Control Test
33%
Mini Asthma Quality of Life Questionnaire
33%
Monoclonal Antibody
16%
Intolerance
16%
Antibody Targeting
16%
Baseline Characteristics
16%
Interleukin-5 (IL-5)
16%
Lack of Response
16%
Retrospective multicenter Study
16%
Patient Profile
16%
Healthcare Resource Utilization
16%
Asthma Control
16%
Clinically Meaningful Improvement
16%
Visit Rate
16%
Clinically Meaningful Difference
16%
Marketing Authorization
16%
Treatment Dosage
16%
Mepolizumab
16%
Reslizumab
16%
Interleukin-5 Receptor
16%
Medicine and Dentistry
Eosinophilic
100%
Asthma
100%
Benralizumab
100%
Corticosteroid Therapy
44%
Oral
44%
Drug Dose Reduction
22%
Asthma Control Test
22%
Quality of Life
22%
Primary Health Care
22%
Emergency Department
22%
Monoclonal Antibody
11%
Mepolizumab
11%
Interleukin 5
11%
Reslizumab
11%
Interleukin 5 Receptor
11%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Benralizumab
100%
Monoclonal Antibody
9%
Mepolizumab
9%
Interleukin 5
9%
Reslizumab
9%
Interleukin 5 Receptor
9%